Judd Hultquist, PhD talks about key variants of SARS-CoV-2 and how is lab is identifying and studying these variants.
Elizabeth McNally, MD, PhD, talks about her recent discoveries advancing muscular dystrophy research.
As the Delta variant of SARS-CoV-2 is causing breakthrough infections in some vaccinated people around the world, scientists at Northwestern Medicine are developing and studying potential next-generation COVID-19 vaccines that could be more effective at preventing and clearing breakthrough infections. Pablo Penaloza-MacMaster, PhD, an assistant professor of Microbiology-Immunology at Feinberg, discusses work in his lab that could lead to better vaccines and treatments for coronaviruses.
As heart conditions like arrhythmia become increasingly common, heart monitoring is becoming an even more important tool for disease prevention and treatment. Northwestern Medicine cardiac electrophysiologist Rod Passman, MD, who has over three decades of experience in the field, reviews the history of cardiac monitoring and looks to the future. He details his pioneering use of implantable heart monitors for arrhythmia in stroke patients and his partnership with a consumer electronics company to bring wearable heart monitors to patients.
Esophageal diseases are extremely common, and symptoms such as trouble swallowing, chest pain, regurgitation and choking diminish quality of life. There can also be psychosocial effects for patients with these diseases, including hypervigilance — a heightened focus on physical symptoms — and symptom-specific anxiety such as fear of choking. Identifying patients with issues could help providers better treat their disease.
An early clinical trial found that a spherical nucleic acid drug developed at Northwestern kills tumor cells in people with the fatal brain cancer glioblastoma. This is the first time a nanotherapeutic has been shown to cross the blood-brain barrier and cause cell death. Lead investigator Priya Kumthekar, MD, explains the results of the study.
Daniel Batlle, MD, professor of medicine in the Division of Nephrology and Hypertension at Northwestern, has been studying ACE2 and its potential therapeutic uses for many years. When the pandemic began, he proposed a hypothesis that soluble ACE2 could treat the SARS-CoV-2 virus and lead to survival and full recovery, and now he has some exciting preliminary results.
Black men are more likely to get prostate cancer and more than twice as likely to die from the disease than other men. Edward Schaeffer, MD, PhD, has developed a research team to better understand this problem. In this show he talks about his latest discoveries, which are paving the way to precision medicine for aggressive prostate cancer. Schaeffer is the chair of the Department of Urology at Northwestern and a Northwestern Medicine urologist with a specialized practice in prostate cancer.
COVID-19 can be a multi-system disease, impacting many organs and the entire nervous system. Igor Koralnik, MD, has been investigating the neurological complications of the disease and published the first study focused on long-term neurologic symptoms in COVID-19 “long haulers.” He explains the study and what he is seeing in the Neuro COVID-19 Clinic at Northwestern Memorial Hospital.
Atopic dermatitis — or eczema — affects about 10 million children in the U.S., and the itching that accompanies this condition can cause pain and distress for kids who can’t always verbalize or quantify how much they’re suffering. But a new wearable sensor developed by Northwestern University scientists could help better monitor scratching and assess the effectiveness of therapies for eczema and other conditions that cause itch. Steve Xu, MD, MSc, talks about the wearable sensor and the critical role it could play in bringing much-needed relief to patients.